Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
November 08, 2022 08:30 ET
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will...
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
November 08, 2022 07:30 ET
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today...
Zai Lab Announces Participation in November Investor Conferences
October 31, 2022 07:52 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
October 18, 2022 07:30 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Launches its first Trust Report
October 14, 2022 07:55 ET
|
Zai Lab Limited
Zai Lab is committed to earning your trust through our environmental, social, and governance (ESG) strategy, which we are calling Trust for LifeZai’s Trust for Life strategy includes three commitments...
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
September 27, 2022 08:00 ET
|
Zai Lab Limited
-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab...
Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting
September 20, 2022 08:03 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Announces Participation in September Investor Conferences
August 23, 2022 07:30 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates
August 09, 2022 16:05 ET
|
Zai Lab Limited
Key pipeline milestones achieved including the BLA acceptance of efgartigimod by China’s NMPA and positive topline results for the KarXT Phase 3 EMERGENT-2 trial Continued revenue growth led by...
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
August 08, 2022 07:02 ET
|
Zai Lab Limited
Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary...